Top

Published in:

02-04-2022 | Myasthenia Gravis | COVID-19

Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab

Authors: Masahiro Mimori, Teppei Komatsu, Takahiro Maku, Hidetaka Mitsumura, Yasuyuki Iguchi

Published in: Neurological Sciences | Issue 7/2022

Abstract

Eculizumab, a humanized monoclonal antibody, is a complement inhibitor indicated for refractory generalized myasthenia gravis (MG). However, there are limited data on the safety of eculizumab for MG during coronavirus disease 2019 (COVID-19) infection. We report a case in which eculizumab was continued for MG after contracting COVID-19, followed by a favorable outcome.

Available only for authorised users

Howard JF, Utsugisawa K, Benatar M et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976–986. https://doi.org/10.1016/s1474-4422(17)30369-1CrossRefPubMed

Cabal-Herrera AM, Mateen FJ (2021) COVID-19 in a patient treated with eculizumab for aquaporin-4 neuromyelitis optica. J Neurol 268:4479–4482. https://doi.org/10.1007/s00415-021-10578-7

Oy UH, Stankovic S, Kelbel C et al (2021) Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19. J Neurol 268:3125–3128. https://doi.org/10.1007/s00415-021-10428-6CrossRef

Pittock SJ, Berthele A, Fujihara K et al (2019) Eculizumab in aquaporin-4–positive neuromyelitis optica spectrum disorder. New Engl J Med 381:614–625. https://doi.org/10.1056/nejmoa1900866CrossRefPubMed

Dhillon S (2018) Eculizumab: a review in generalized myasthenia gravis. Drugs 78:367–376. https://doi.org/10.1007/s40265-018-0875-9CrossRefPubMedPubMedCentral

Chowdhury MA, Hossain N, Kashem MA et al (2020) Immune response in COVID-19: a review. J Infect Public Heal 13:1619–1629. https://doi.org/10.1016/j.jiph.2020.07.001CrossRef

Rother RP, Rollins SA, Mojcik CF et al (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25:1256–1264. https://doi.org/10.1038/nbt1344CrossRefPubMed

Annane D, Heming N, Grimaldi-Bensouda L et al (2020) Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study. Eclinicalmedicine 28:100590. https://doi.org/10.1016/j.eclinm.2020.100590CrossRefPubMedPubMedCentral

Title: Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab
Authors: Masahiro Mimori
Teppei Komatsu
Takahiro Maku
Hidetaka Mitsumura
Yasuyuki Iguchi
Publication date: 02-04-2022
Publisher: Springer International Publishing
Keywords: Myasthenia Gravis
Pneumonia
COVID-19
Prednisolone
Published in: Neurological Sciences / Issue 7/2022
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-022-05922-2

At a glance: The STEP trials

Springer Medicine

Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2022

Predictors of unemployment status in people with relapsing multiple sclerosis: a single center experience

The altered multiscale dynamics of spontaneous brain activity in depression with Parkinson’s disease

Brain magnetic resonance imaging and severity of neurological disease in Wilson’s disease — the neuroradiological correlations

Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance

Phase angle, muscle mass, and functionality in patients with Parkinson’s disease

Epidemiological and clinical characteristics of patients with late-onset Creutzfeldt-Jakob disease